Journal of Obesity & Metabolic Syndrome最新文献

{"title":"Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Ji-Hee Haam,&nbsp;Bom Taeck Kim,&nbsp;Eun Mi Kim,&nbsp;Hyuktae Kwon,&nbsp;Jee-Hyun Kang,&nbsp;Jung Hwan Park,&nbsp;Kyoung-Kon Kim,&nbsp;Sang Youl Rhee,&nbsp;Yang-Hyun Kim,&nbsp;Ki Young Lee","doi":"10.7570/jome23031","DOIUrl":"https://doi.org/10.7570/jome23031","url":null,"abstract":"<p><p>The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m² and obesity as a BMI ≥25 kg/m², based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index.","authors":"Ye-Lim Shin,&nbsp;Heesoh Yoo,&nbsp;Joo Young Hong,&nbsp;Jooeun Kim,&nbsp;Kyung-do Han,&nbsp;Kyu-Na Lee,&nbsp;Yang-Hyun Kim","doi":"10.7570/jomes22047","DOIUrl":"https://doi.org/10.7570/jomes22047","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of type 2 diabetes mellitus has continued to rise. Although many studies have focused on the connection between weight loss and glucose control, only a few studies have investigated the association between body mass index (BMI) and glucose control status. We examined the association between glucose control and obesity.</p><p><strong>Methods: </strong>We analyzed 3,042 participants with diabetes mellitus who were aged ≥19 years when they participated in the 2014 to 2018 Korean National Health and Nutrition Examination Survey. The participants were divided into four groups according to their BMI (<18.5, 18.5-23, 23-25, and ≥25 kg/m²). We used guidelines from the Korean Diabetes Association to compare the glucose control in those groups, with a cross-sectional design, multivariable logistic regression, and glycosylated hemoglobin <6.5% as the reference.</p><p><strong>Results: </strong>Overweight males aged ≥60 years had a high odds ratio (OR) for degraded glucose control (OR, 1.706; 95% confidence interval [CI], 1.151 to 2.527). Among obese females, those in the ≥60 years age group showed an increased OR for uncontrolled diabetes (OR, 1.516; 95% CI, 1.025 to 1.892). Moreover, in females, the OR for uncontrolled diabetes tended to increase as the BMI increased (<i>P</i>=0.017).</p><p><strong>Conclusion: </strong>Obesity is associated with uncontrolled diabetes in female patients with diabetes who are aged ≥60 years. Physicians should closely monitor this group for diabetes control.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"55-63"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/24/jomes-32-1-55.PMC10088554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Rate Responses at Rest, during Exercise and after Exercise Periods in Relation to Adiposity Levels among Young Nigerian Adults.","authors":"Uchechukwu Dimkpa,&nbsp;Robert C Godswill,&nbsp;Peter Okonudo,&nbsp;David Ikwuka","doi":"10.7570/jomes22055","DOIUrl":"https://doi.org/10.7570/jomes22055","url":null,"abstract":"<p><strong>Background: </strong>There is a dearth of comparative studies on heart rate (HR) abnormalities at rest, chronotropic responses during submaximal exercise, and such responses during recovery from submaximal exercise between healthy-weight and overweight/obese young adults.</p><p><strong>Methods: </strong>Eighty healthy young adults (30 men and 50 women) aged 19 to 33 years participated in the present study. A symptom-limited, submaximal, cycle ergometer exercise test of intensity targeted at 60% to 70% of the subject's age-predicted maximum HR was performed. The HR, blood pressure, and minute ventilation were measured at rest and during exercise. Post-exercise, HR was first measured at 1 minute of recovery and then every 2 minutes until the 5th minute.</p><p><strong>Results: </strong>Our results showed significantly higher resting HR (<i>P</i><0.001), lower percentage HR reserve during exercise (<i>P</i><0.001), and slower HR recovery after exercise (<i>P</i><0.05, <i>P</i><0.01, or <i>P</i><0.001) in overweight/obese men and women than in the non-overweight/obese controls. The prevalence of high resting HR, submaximal chronotropic incompetence, and blunted HR recovery were more common in the overweight/obese individuals than in the healthy-weight controls. Peak VO₂ and ventilatory equivalent for oxygen were associated with resting HR, exercise HR parameters, and post-exercise HR recovery indices in both men and women.</p><p><strong>Conclusion: </strong>High resting HR, submaximal chronotropic incompetence, and blunted HR recovery in overweight/obese individuals in this study may be attributed to poor cardiorespiratory fitness and low respiratory efficiency.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"87-97"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/b3/jomes-32-1-87.PMC10088548.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9643090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.","authors":"Rachel Sinha,&nbsp;Dimitris Papamargaritis,&nbsp;Jack A Sargeant,&nbsp;Melanie J Davies","doi":"10.7570/jomes22067","DOIUrl":"https://doi.org/10.7570/jomes22067","url":null,"abstract":"<p><p>The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people with T2DM, from monotherapy through to insulin add-on in global populations, with another two trials dedicated to Japanese population. Over periods of treatment up to 104 weeks, once weekly tirzepatide 5 to 15 mg reduced glycosylated hemoglobin (1.87% to 3.02%), body weight (5.4 to 12.9 kg) and improved multiple cardiometabolic risk factors (including reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipids) across the T2DM spectrum. Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine. All tirzepatide doses were well tolerated with similar side-effect profile to the GLP-1 receptor analogues. In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"25-45"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/6e/jomes-32-1-25.PMC10088547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Loss Prediction after Metabolic and Bariatric Surgery.","authors":"Ji Yeon Park","doi":"10.7570/jomes23008","DOIUrl":"https://doi.org/10.7570/jomes23008","url":null,"abstract":"<p><p>Metabolic/bariatric surgery is currently the most effective measure to treat morbid obesity and obesity-related comorbidities such as type 2 diabetes. It has proven effective not only in terms of short-term weight loss, but also in maintaining the lower body weight for several decades. Such weight loss improves patient quality of life and extends life expectancy. It is crucial for patients to understand the likely results of a given bariatric procedure so that they can make an informed decision about whether to undergo surgery. The amount of weight loss after metabolic/bariatric surgery is usually the most important outcome of interest to patients considering surgical treatment. It is also the most common primary endpoint for healthcare providers. Patients undergoing surgery want tangible and realistic expectations about how much weight they could lose after surgery, and healthcare professionals need to determine at each follow-up visit after surgery whether patients are on track to reach their weight loss target so they can provide timely intervention to patients with insufficient weight loss or weight regain. Weight loss after metabolic/bariatric surgery is influenced by many clinical variables, including initial body mass index, age, gender, ethnicity, and type of surgery. A well-validated chronological weight loss prediction model would enable patient-centered counseling and goal setting. This review summarizes and compares several publicly available prediction models.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"46-54"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/58/jomes-32-1-46.PMC10088553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9289089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic Profiling of Subcutaneous Adipose Tissue in Relation to Bariatric Surgery: A Retrospective, Pooled Re-analysis.","authors":"Youdinghuan Chen","doi":"10.7570/jomes22065","DOIUrl":"https://doi.org/10.7570/jomes22065","url":null,"abstract":"<p><strong>Background: </strong>Bariatric surgery is the most effective intervention for weight loss possibly through modulating subcutaneous adipose tissue (SAT) molecular programs. The post-operative molecular and biological impacts, including gene expression, deserve in-depth investigation especially given the small sample sizes in the literature.</p><p><strong>Methods: </strong>Five existing datasets (n=237 SATs) were re-processed and corrected for batch-to-batch variation. Unsupervised approaches and robust linear mixed effect model were used to compare gene expression post- (n=126) to pre-operation (n=111).</p><p><strong>Results: </strong>Post-operative SATs showed distinct global gene expression. Forty-four and 395 genes were over- and under-expressed post-operation (all Bonferroni <i>P</i><0.05). The under-expressed genes significantly enriched for 21 biological processes/pathways (all Bonferroni <i>P</i><0.05), 17 (76.2%) and two (9.5%) directly involved in immunity and amino/proteo-glycan metabolism, respectively.</p><p><strong>Conclusion: </strong>Post-operative SATs might adopt distinct transcriptomic landscapes and undergo a reduction in immune-related processes and amino/proteo-glycan metabolism.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"98-102"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/5f/jomes-32-1-98.PMC10088552.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9293281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Function of Body Mass Index in the Older with Osteosarcopenia: A Systematic Review and Meta-analysis.","authors":"Yang Du,&nbsp;Shuting Tao,&nbsp;Chorong Oh,&nbsp;Jaekyung No","doi":"10.7570/jomes22057","DOIUrl":"https://doi.org/10.7570/jomes22057","url":null,"abstract":"<p><strong>Background: </strong>Due to the aging population worldwide, diseases that frequently attack elderly people, such as sarcopenia and osteoporosis, are major public health issues.</p><p><strong>Methods: </strong>This study used a systematic review and meta-analysis to examine the associations among body mass index (BMI), sarcopenia, and bone mineral density (BMD) in a group of adults older than 60 years. Eight studies with a total of 18,783 subjects were examined using a random effect model.</p><p><strong>Results: </strong>In sarcopenia patients, total hip BMD (d=0.560; 95% confidence interval [CI], 0.438 to 0.681; <i>P</i><0.01; I²=53.755%), femoral neck BMD (d=0.522; 95% CI, 0.423 to 0.621; <i>P</i><0.01; I²=77.736%) and lumbar spine BMD (d=0.295; 95% CI, 0.111 to 0.478; <i>P</i><0.01; I²=66.174%) were lower than in control subjects. Additionally, BMI (d=0.711; 95% CI, 0.456 to 0.996; <i>P</i><0.01; I²=97.609%) correlated with the BMD of the total hip, femoral neck, and lumbar spine. That is, sarcopenia patients with low BMD levels in the total hip, femoral neck, and lumbar spine also had low fat levels. Thus, sarcopenia patients with low BMD in the total hip, femoral neck and lumbar spine and low BMI could have a higher than average risk of osteosarcopenia. No sex effects were significant (<i>P</i>>0.05) for any variable.</p><p><strong>Conclusion: </strong>BMI could be a key point in osteosarcopenia, suggesting that a low body weight could be facilitate the transition from sarcopenia to osteosarcopenia.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"77-86"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/42/jomes-32-1-77.PMC10088551.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9470299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Kyoung-Kon Kim, Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Jung Hwan Park, Sang Youl Rhee, Eonju Jeon, Eungu Kang, Ga Eun Nam, Hye Yeon Koo, Jeong-Hyun Lim, Jo-Eun Jeong, Jong-Hee Kim, Jong Won Kim, Jung Ha Park, Jun Hwa Hong, Sang Eok Lee, Se Hee Min, Seung Jun Kim, Sunyoung Kim, Yang-Hyun Kim, Yeon Ji Lee, Yoon Jeong Cho, Young-Jun Rhie, Youn-Hee Kim, Jee-Hyun Kang, Chang Beom Lee","doi":"10.7570/jomes23016","DOIUrl":"10.7570/jomes23016","url":null,"abstract":"<p><p>The goal of the 8th edition of the Clinical Practice Guidelines for Obesity is to help primary care physician provide safe, effective care to patients with obesity by offering evidence-based recommendations to improve the quality of treatment. The Committee for Clinical Practice Guidelines comprised individuals with multidisciplinary expertise in obesity management. A steering board of seven experts oversaw the entire project. Recommendations were developed as the answers to key questions formulated in patient/problem, intervention, comparison, outcomes (PICO) format. Guidelines underwent multi-level review and cross-checking and received endorsement from relevant scientific societies. This edition of the guidelines includes criteria for diagnosing obesity, abdominal obesity, and metabolic syndrome; evaluation of obesity and its complications; weight loss goals; and treatment options such as diet, exercise, behavioral therapy, pharmacotherapy, and bariatric and metabolic surgery for Korean people with obesity. Compared to the previous edition of the guidelines, the current edition includes five new topics to keep up with the constantly evolving field of obesity: diagnosis of obesity, obesity in women, obesity in patients with mental illness, weight maintenance after weight loss, and the use of information and communication technology-based interventions for obesity treatment. This edition of the guidelines features has improved organization, more clearly linking key questions in PICO format to recommendations and key references. We are confident that these new Clinical Practice Guidelines for Obesity will be a valuable resource for all healthcare professionals as they describe the most current and evidence-based treatment options for obesity in a well-organized format.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"1-24"},"PeriodicalIF":4.7,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/af/jomes-32-1-1.PMC10088549.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9836238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing the Association of Visceral Adipose Tissue Growth Differentiation Factor-15 and MicroRNA in Type 2 Diabetes Mellitus.","authors":"Dipayan Roy, Purvi Purohit, Manoj Khokhar, Anupama Modi, Ravindra Kumar Gayaprasad Shukla, Ramkaran Chaudhary, Shrimanjunath Sankanagoudar, Praveen Sharma","doi":"10.7570/jomes22010","DOIUrl":"10.7570/jomes22010","url":null,"abstract":"<p><strong>Background: </strong>Growth differentiation factor-15 (GDF-15) is involved in insulin resistance and diabetes. In this study, we determine the associations of GDF-15 with miR-181b-5p, miR-330-3p, mothers against decapentaplegic homolog 7 (SMAD7), and insulin resistance in visceral adipose tissue (VAT) and peripheral blood mononuclear cells (PBMCs) in type 2 diabetes mellitus (T2DM) patients.</p><p><strong>Methods: </strong>Sixty patients, equally divided into those with T2DM and non-diabetic controls, were recruited for gene expression analysis. Protein-protein interaction (STRING), target prediction (miRNet), and functional enrichment were conducted accordingly.</p><p><strong>Results: </strong>Our study showed that VAT and PBMCs had similar expression profiles, where GDF-15 and miR-181b-5p were upregulated, whereas SMAD7 and miR-330-3p were downregulated. Serum GDF-15 could differentiate between T2DM and non-diabetic patients (<i>P</i><0.001). Target prediction revealed a microRNA (miRNA)-messenger RNA regulatory network, transcription factors, and functional enrichment for the miRNA that suggested involvement in T2DM pathogenesis.</p><p><strong>Conclusion: </strong>VAT GDF-15 is associated with insulin resistance and is possibly regulated by miR-181b-5p, miR-330-3p, and SMAD7 in T2DM.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"64-76"},"PeriodicalIF":4.7,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/75/jomes-32-1-64.PMC10088550.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9643116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bariatric Surgery in Kidney Transplant Candidates and Recipients: Experience at an Asian Center.","authors":"Sarah Ying Tse Tan,&nbsp;Phong Ching Lee,&nbsp;Sonali Ganguly,&nbsp;Peng Chin Kek,&nbsp;Terence Kee,&nbsp;Quan Yao Ho,&nbsp;Sobhana Thangaraju","doi":"10.7570/jomes21090","DOIUrl":"https://doi.org/10.7570/jomes21090","url":null,"abstract":"<p><strong>Background: </strong>Kidney transplant (KT) candidates and recipients with obesity experience more frequent complications such as infection, poorer allograft outcomes, diabetes, and mortality, limiting their eligibility for transplantation. Bariatric surgery (BS) is not commonly performed among KT patients given concerns about immunosuppression absorption, wound healing, infections, and graft outcomes. Its role has not been described before in an Asian KT patient setting.</p><p><strong>Methods: </strong>A retrospective review of patients who underwent BS at the largest KT center in Singapore from 2008 to 2020 was conducted. Metabolic outcomes, immunosuppression doses, graft outcomes, and mortality were studied.</p><p><strong>Results: </strong>Seven patients underwent BS and KT (4 underwent BS before KT, 3 underwent BS after KT; 4 underwent sleeve gastrectomy, 3 underwent gastric bypass). Mean total weight losses of 23.8% at 1 year and 18.6% at 5 years post-BS were achieved. Among the five patients with diabetes, glycemic control improved after BS. There were no deaths in the first 90 days or graft loss in the first year after KT and BS. Patients who underwent BS after KT had no significant changes in immunosuppression dose.</p><p><strong>Conclusion: </strong>BS can be safely performed in KT recipients and candidates and results in sustainable weight losses and improvements in metabolic comorbidities. Although no major complications were observed in our study, close monitoring of this complex group of patients is imperative.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"31 4","pages":"325-333"},"PeriodicalIF":5.2,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/ab/jomes-31-4-325.PMC9828702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9097786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}